Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics
Caio Perez Gomes, Danilo Euclides Fernandes, Fernanda M. S. Casimiro, et al.
Frontiers in Cellular and Infection Microbiology (2020) Vol. 10
Open Access | Times Cited: 144

Showing 1-25 of 144 citing articles:

Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development
Miao-Miao Zhao, Weili Yang, Fangyuan Yang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 447
The SARS‐CoV‐2 main protease (Mpro): Structure, function, and emerging therapies for COVID‐19
Qing Hu, Yuan Xiong, Guanghao Zhu, et al.
MedComm (2022) Vol. 3, Iss. 3
Open Access | Times Cited: 144
Development of optimized drug-like small molecule inhibitors of the SARS-CoV-2 3CL protease for treatment of COVID-19
Hengrui Liu, Sho Iketani, Arie Zask, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 78
Structural and non-structural proteins in SARS-CoV-2: potential aspects to COVID-19 treatment or prevention of progression of related diseases
Sareh Kakavandi, Iman Zare, Maryam Vaezjalali, et al.
Cell Communication and Signaling (2023) Vol. 21, Iss. 1
Open Access | Times Cited: 62
Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies
Yuwen Zhou, Yao Xie, Liansha Tang, et al.
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 100
SARS-CoV-2 Main Protease Drug Design, Assay Development, and Drug Resistance Studies
Bin Tan, Ryan Joyce, Haozhou Tan, et al.
Accounts of Chemical Research (2022) Vol. 56, Iss. 2, pp. 157-168
Open Access | Times Cited: 61
Niclosamide—A promising treatment for COVID‐19
Shivani Singh, Anne Weiss, James A. Goodman, et al.
British Journal of Pharmacology (2022) Vol. 179, Iss. 13, pp. 3250-3267
Open Access | Times Cited: 58
Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications
Jamal Majidpoor, Keywan Mortezaee
Biomedicine & Pharmacotherapy (2021) Vol. 145, pp. 112419-112419
Open Access | Times Cited: 56
Choosing a cellular model to study SARS-CoV-2
Gabriel Augusto Pires de Souza, Marion Le Bideau, Céline Boschi, et al.
Frontiers in Cellular and Infection Microbiology (2022) Vol. 12
Open Access | Times Cited: 42
Structure-based design of pan-coronavirus inhibitors targeting host cathepsin L and calpain-1
Xiong Xie, Qiaoshuai Lan, Jinyi Zhao, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 11
SiteMine: Large‐scale binding site similarity searching in protein structure databases
Thorben Reim, Christiane Ehrt, Joel Graef, et al.
Archiv der Pharmazie (2024) Vol. 357, Iss. 5
Open Access | Times Cited: 8
Precision nutrition to reset virus-induced human metabolic reprogramming and dysregulation (HMRD) in long-COVID
A. Satyanarayan Naidu, Chin‐Kun Wang, Pingfan Rao, et al.
npj Science of Food (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 8
Peptidomimetics as potent dual SARS-CoV-2 cathepsin-L and main protease inhibitors: In silico design, synthesis and pharmacological characterization
Tania Ciaglia, Vincenzo Vestuto, Veronica Di Sarno, et al.
European Journal of Medicinal Chemistry (2024) Vol. 266, pp. 116128-116128
Open Access | Times Cited: 7
Peptidomimetic nitrile warheads as SARS-CoV-2 3CL protease inhibitors
Bing Bai, Elena Arutyunova, Muhammad Bashir Khan, et al.
RSC Medicinal Chemistry (2021) Vol. 12, Iss. 10, pp. 1722-1730
Open Access | Times Cited: 49
Dual Inhibitors of Main Protease (MPro) and Cathepsin L as Potent Antivirals against SARS-CoV2
Santanu Mondal, Yongzhi Chen, G.J. Lockbaum, et al.
Journal of the American Chemical Society (2022) Vol. 144, Iss. 46, pp. 21035-21045
Open Access | Times Cited: 35
An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients
Rajan Ravichandran, Krishna Mohan Surapaneni, Suresh Kumar Sukumaran, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 33
COVID-19 and the promise of small molecule therapeutics: Are there lessons to be learnt?
Wei Shen Ho, Ruirui Zhang, Yeong Lan Tan, et al.
Pharmacological Research (2022) Vol. 179, pp. 106201-106201
Open Access | Times Cited: 29
COVID-19 receptor and malignant cancers: Association of CTSL expression with susceptibility to SARS-CoV-2
Lianmei Zhang, Chunli Wei, Dabing Li, et al.
International Journal of Biological Sciences (2022) Vol. 18, Iss. 6, pp. 2362-2371
Open Access | Times Cited: 29
SARS-CoV-2 Spike Protein Is Capable of Inducing Cell–Cell Fusions Independent from Its Receptor ACE2 and This Activity Can Be Impaired by Furin Inhibitors or a Subset of Monoclonal Antibodies
Nina Reuter, Xiaohan Chen, Barbara Kropff, et al.
Viruses (2023) Vol. 15, Iss. 7, pp. 1500-1500
Open Access | Times Cited: 17
S Protein, ACE2 and Host Cell Proteases in SARS-CoV-2 Cell Entry and Infectivity; Is Soluble ACE2 a Two Blade Sword? A Narrative Review
Reza Nejat, Maziar Fayaz Torshizi, David J. Najafi
Vaccines (2023) Vol. 11, Iss. 2, pp. 204-204
Open Access | Times Cited: 15
Compensational role between cathepsins
Urša Pečar Fonović, Janko Kos, Ana Mitrović
Biochimie (2024) Vol. 226, pp. 62-76
Open Access | Times Cited: 6
Impact of Cathepsin L Inhibition in SARS-CoV-2 Infection and Potential Therapeutic Interventions
Muteeba Azhar, Asma Irshad, Ansar Zubair, et al.
BioScientific Review (2025) Vol. 6, Iss. 4, pp. 100-115
Open Access
Research progress and perspectives of dual-target inhibitors
Xiaojing Pang, Wenyan Xu, Jing Liang, et al.
European Journal of Medicinal Chemistry (2025) Vol. 289, pp. 117453-117453
Closed Access
Mechanisms of coronavirus infectious disease 2019-related neurologic diseases
Robyn S. Klein
Current Opinion in Neurology (2022) Vol. 35, Iss. 3, pp. 392-398
Open Access | Times Cited: 26
Receptors and Cofactors That Contribute to SARS-CoV-2 Entry: Can Skin Be an Alternative Route of Entry?
Manon Barthe, Leslie Hertereau, Noura Lamghari, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 7, pp. 6253-6253
Open Access | Times Cited: 14
Page 1 - Next Page

Scroll to top